Request Demo
Last update 25 May 2025
Eculizumab biosimilar(Biocad Medical, Inc.)
Last update 25 May 2025
Overview
Basic Info
Drug Type Biosimilar, Monoclonal antibody |
Synonyms Eculizumab biosimilar, 依库丽单抗生物类似药 (Biocad Medical, Inc.), BCD-148 |
Target |
Action inhibitors |
Mechanism C5 inhibitors(Complement C5 inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPhase 3 |
First Approval Date- |
Regulation- |
Login to view timeline
Structure/Sequence
Sequence Code 66437L
The sequence is quoted from: *****
Sequence Code 66453H
The sequence is quoted from: *****
Related
3
Clinical Trials associated with Eculizumab biosimilar(Biocad Medical, Inc.)NCT06987864
An Extension Clinical Study of BCD-148 (JSC BIOCAD) for the Treatment of Patients With Paroxysmal Nocturnal Hemoglobinuria Previously Treated in Clinical Study No. BCD-148-2/NOCTURN
NCT04060264
Randomized, Open-Label, International, Multi-center, Comparative Study of Efficacy and Safety of BCD-148 (JSC BIOCAD, Russia) and Soliris® in Patients With Paroxysmal Nocturnal Hemoglobinuria
NCT04027803
A Double-blind, Randomized Clinical Study to Compare the Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of Single Intravenous Doses of BCD-148 (JSC BIOCAD, Russia) and Soliris® in Healthy Volunteers
100 Clinical Results associated with Eculizumab biosimilar(Biocad Medical, Inc.)
Login to view more data
100 Translational Medicine associated with Eculizumab biosimilar(Biocad Medical, Inc.)
Login to view more data
100 Patents (Medical) associated with Eculizumab biosimilar(Biocad Medical, Inc.)
Login to view more data
100 Deals associated with Eculizumab biosimilar(Biocad Medical, Inc.)
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Hemoglobinuria, Paroxysmal | Phase 3 | Russia | 04 Apr 2019 | |
| Hemoglobinuria, Paroxysmal | Phase 3 | Russia | 04 Apr 2019 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 1 | - | 78 | (BCD-148) | rsvthbmijr(wbowqwgebf) = tdbwkoplmr sgugvaggof (jqseowxctv, maganoxpuw - gxehrsoapk) View more | - | 15 May 2020 | |
(Soliris) | rsvthbmijr(wbowqwgebf) = ipapopvahi sgugvaggof (jqseowxctv, lwqkqctyun - lfusazrerx) View more |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free